- AZD-8055
-
- $36.00 / 5mg
-
2026-02-01
- CAS:1009298-09-2
- Min. Order:
- Purity: 98.08%
- Supply Ability: 10g
- AZD-8055
-
- $7.00 / 1KG
-
2019-09-02
- CAS:1009298-09-2
- Min. Order: 1KG
- Purity: 99%
- Supply Ability: JD 495
- AZD-8055
-
- $2.00 / 1kg
-
2019-07-06
- CAS:1009298-09-2
- Min. Order: 1kg
- Purity: 99%
- Supply Ability: 100kg
|
| | AZD-8055 Basic information |
| Product Name: | AZD-8055 | | Synonyms: | CS-1935;{5-[2,4-Bis-(3-methyl-morpholin-4-yl)-pyrido[2,3-d]pyrimidin-7-yl]-2-methoxy-phenyl}-methanol;AZD-8055; AZD8055; AZD 8055.;AZD 8055 [5-[2,4-Bis((3S)-3-methylmorpholin-4-yl)pyrido[2,3-d]pyrimidin-7-yl]-2-methoxyphenyl]methanol;AZD8055, >=98%;Propanoic acid, 2,2-dimethyl-, [5-(2,4-dichloropyrido[2,3-d]pyrimidin-7-yl)-2-methoxyphenyl]methyl ester;(5-{2,4-dichloropyrido[2,3-d]pyriMidin-7-yl}-2-Methoxyphenyl)Methyl 2,2-diMethylpropanoate;[5-[2,4-Bis((3S)-3-MethylMorpholin-4-yl)pyrido[ | | CAS: | 1009298-09-2 | | MF: | C25H31N5O4 | | MW: | 465.54 | | EINECS: | | | Product Categories: | Aromatics;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals;Protein Kinase Inhibitors and Activators;Akt;mTOR;PI3K;Inhibitors;PI3K/Akt/mTOR | | Mol File: | 1009298-09-2.mol |  |
| | AZD-8055 Chemical Properties |
| Melting point | 204 - 207°C | | Boiling point | 694.3±65.0 °C(Predicted) | | density | 1.248 | | storage temp. | -20°C | | solubility | Soluble in DMSO (up to 30 mg/ml) | | pka | 14.20±0.10(Predicted) | | form | Yellow powder. | | color | Yellow | | Stability: | Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 2 months. |
| Safety Statements | 24/25 | | HS Code | 29335990 |
| | AZD-8055 Usage And Synthesis |
| Description | AZD8055 (1009298-09-2) is a potent and highly selective inhibitor of mammalian target of rapamycin kinase (mTOR) kinase (IC50 = 0.8 nM).1,2 mTOR acts as a nutrient/energy/redox sensor and a controller of protein synthesis – as such it is a very important target for cancer research. It has been investigated as a potential chemotherapeutic for various cancers.3-7 | | Uses | A novel ATP-competitive inhibitor of mTOR with an IC50 of 0.8 nM. | | Uses | A potent, selective, and orally bioavailable ATP-competitive mTOR kinase inhibitor with an IC50 of 0.8 nM. It inhibits the phosphorylation of mTORC1 substrates p70S6K and 4E-BP1 as well as phosphoryla
tion of the mTORC2 substrate AKT and downstream proteins. The rapamycin-resistant T37/46 phosphorylation sites on 4E-BP1 were fully inhibited by AZD8055, resulting in significant inhibition of cap-dep
endent translation. In vitro, AZD8055 potently inhibits proliferation and induces autophagy in H838 and A549 cells. In vivo, AZD8055 induces a dose-dependent pharmacodynamic effect on phosphorylated S
6 and phosphorylated AKT at plasma concentrations leading to tumor growth inhibition. | | Definition | ChEBI: AZD-8055 is a pyridopyrimidine that is pyrido[2,3-d]pyrimidine which is substituted at positions 2 and 4 by (3S)-3-methylmorpholin-4-yl groups and at position 5 by a 3-(hydroxymethyl)-4-methoxyphenyl group. It is an mTOR complex 1/2 (mTORC1/2) dual inhibitor [mTOR = mammalian target of rapamycin]. It has a role as a mTOR inhibitor, an apoptosis inducer and an antineoplastic agent. It is a member of benzyl alcohols, a tertiary amino compound, a pyridopyrimidine and a member of morpholines. | | target | mTOR (full length) | | storage | Store at -20°C | | References | [1] CHRISTINE M CHRESTA. AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity.[J]. Cancer research, 2010, 70 1: 288-298. DOI:10.1158/0008-5472.can-09-1751
[2] KURT G. PIKE . Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: The discovery of AZD8055 and AZD2014[J]. Bioorganic & Medicinal Chemistry Letters, 2013, 23 5: Pages 1212-1216. DOI:10.1016/j.bmcl.2013.01.019
[3] SARAH V HOLT. Enhanced apoptosis and tumor growth suppression elicited by combination of MEK (selumetinib) and mTOR kinase inhibitors (AZD8055).[J]. Cancer research, 2012: 1804-1813. DOI:10.1158/0008-5472.can-11-1780
[4] L WILLEMS. The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia[J]. Leukemia, 2011, 26 6: 1195-1202. DOI:10.1038/leu.2011.339
[5] SHAORU LI. The mTOR inhibitor AZD8055 inhibits proliferation and glycolysis in cervical cancer cells.[J]. Oncology Letters, 2013: 717-721. DOI:10.3892/ol.2012.1058
[6] QIANG LI . The dual mTORC1 and mTORC2 inhibitor AZD8055 inhibits head and neck squamous cell carcinoma cell growth in vivo and in vitro[J]. Biochemical and biophysical research communications, 2013, 440 4: Pages 701-706. DOI:10.1016/j.bbrc.2013.09.130
[7] MIN HU. AZD8055 induces cell death associated with autophagy and activation of AMPK in hepatocellular carcinoma.[J]. Oncology reports, 2014: 649-656. DOI:10.3892/or.2013.2890 |
| | AZD-8055 Preparation Products And Raw materials |
|